The disclosure provides nonsteroidal anti-inflammatory compositions and methods of use thereof. Specifically, the disclosure provides cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory compositions derived from placenta and/or from MSC cells isolated therefrom, methods for producing said compositions, and uses thereof to treat chronic and acute inflammatory conditions and diseases.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

The invention relates to placenta-derived matrix, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells, delivering cells, promoting differentiation of stem cells or tissue-specific progenitor cells, and repairing, replacing, regenerating, filling, reducing or inhibiting scarring of defects using the same. The invention further relates to methods of coating placenta-derived matrix on a surface or injecting the placenta-derived matrix into a site of interest.

Provided are a method for obtaining endometrial mesenchymal stem cells from human menstrual blood and the endometrial mesenchymal stem cells prepared thereby. The method include: 1) subjecting an aliquot of menstrual blood to cascade filtration through graded cell strainers of decreasing mesh sizes to separate tissue debris, wherein said cell strainers include a filter-through cell strainer for collecting filtrate and a retention cell strainer for collecting retentate, wherein the mesh size of the retention cell strainer is smaller than that of the filter-through cell strainer; 2) collecting the retentate on the retention cell strainer as the tissue debris; 3) culturing the tissue debris in a mesenchymal stem cells medium; and 4) collecting adherent cells as the endometrial mesenchymal stem cells.

The present invention relates to methods for obtaining skeletal muscle derived cells (SMDC), and the use of SMDCs in a method of preventing and/or treating neuromyopathies and/or myopathies, wherein the neuromyopathy and/or myopathy is incontinence, in particular a urinary and/or an anal or fecal incontinence.

This disclosure relates to methods of making vascular smooth muscle like cells from precursor stem cells. In certain embodiments the vascular smooth muscle like cells are able to contract in response to vasoactive agents, In certain embodiments, the methods comprise contacting pluripotent stem cells with a mesoderm induction growth medium, followed by replicating the cells in a serum-free vascular smooth muscle cell growth medium in the presence of collagen, and purifying replicated cells that express cadherin-2. In certain embodiments, the purified cells are used to treat or prevent a cardiovascular disease or condition.

Provided is a method for producing serum that exhibits improved cell proliferation activity. A method for producing serum for culturing mammalian cells, comprising: maintaining blood collected from a first mammal at a temperature between 15° C. and 25° C. for up to 48 hours and preparing serum from the blood.

The invention generally relates to cells and compositions comprising same for use in cell therapy, to methods of obtaining same, and to use of same in cell therapy. In one aspect, the invention provides a method for forming a cell composition from a tissue sample, the method comprising: providing a tissue sample comprising cells; contacting the sample with a polymer in binding conditions, said binding conditions being conditions that enable binding of cells in the sample to the polymer, so that said cells are bound to the polymer; culturing the cells bound to the polymer under conditions and for a time that allows the cell number to increase; providing conditions to induce a phase change of the polymer; thereby forming a cell composition from a tissue sample.

A system that easily and stably separates various living cells of interest from a living body-derived tissue, the system including: a suspension unit that prepares a suspension by adding a proteolytic enzyme solution to a living body-derived tissue based on a parameter and shaking the tissue to which the solution has been added; a measurement unit that acquires information regarding the suspension; and an analysis unit that specifies a position of living cells from the information acquired by the measurement unit. Methods for separating various living cells of interest from a living body-derived tissue are also disclosed.

Haematopoietic stem cell mobilization is a process whereby haematopoietic stem cells are stimulated out of the bone marrow space. Before HSC can mobilize, they must be dislodged and released from the BM stem cell niche in which they reside and are retained by adhesive interactions. Accordingly, in an aspect of the present invention there is provided a method for enhancing dislodgement of HSC and their precursors and progenitors thereof from a BM stem cell binding ligand in vivo or ex vivo, said method comprising administering in vivo or ex vivo an effective amount of an antagonist of an a 9 integrin or an active portion thereof to the BM stem cell niche. Once mobilized to the peripheral blood (PB) the HSC may be collected for transplant. Methods which enhance mobilization of the HSC can also improve treatments of haematological disorders.